Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CD19-CAR(Mem) T-cells + Cyclophosphamide + Fludarabine + Mesna|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CD19-CAR(Mem) T-cells||CD19-CAR.CD45RA-negative T-cells||CD19-CAR(Mem) T-cells are a preparation of CD45RA-negative T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19, containing 4-1BB and CD3-zeta signaling domains and a variable fragment of a CD19 antibody, which may potentially lead to tumor cell lysis (PMID: 24888271).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Mesna||Mesnex||D-7093|UCB 398|MSA|mercaptoethane sulfonate|Mesnum|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04881240||Phase I||CD19-CAR(Mem) T-cells + Cyclophosphamide + Fludarabine + Mesna||Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia||Recruiting||USA||0|